Cantor Fitzgerald Reiterates Overweight on Aclaris Therapeutics (ACRS)

Cantor Fitzgerald reiterated an Overweight rating and $50.00 price target on Aclaris Therapeutis (NASDAQ: ACRS) following the company's announced positive topline data from its two Phase 2 trials of A-101 45% topical solution. ACRS will likely move forward with the twiceweekly formulation since the results were better. Although there was a sizeable placebo rate, Cantor believes physicians will care about the percent of all treated warts that were cleared.

To be conservative, Cantor only has peak sales for A-101 in warts of $120MM. This product could be the first FDA approved treatment for common warts.

For an analyst ratings summary and ratings history on Aclaris Therapeutis click here. For more ratings news on Aclaris Therapeutis click here.

Shares of Aclaris Therapeutis closed at $25.38 yesterday.

You May Also Be Interested In

• Goldman Sachs Upgrades Plains GP Holdings, L.P (PAGP) to Neutral
• Freedom Broker Starts Royal Caribbean Cruises (RCL) at Buy
• UBS Double Upgrades China Resources Power Holdings (836:HK) (CRPJY) to Buy